160 related articles for article (PubMed ID: 25743805)
1. Overexpression of Tbx3 predicts poor prognosis of patients with resectable pancreatic carcinoma.
Wang HC; Meng QC; Shan ZZ; Yuan Z; Huang XY
Asian Pac J Cancer Prev; 2015; 16(4):1397-401. PubMed ID: 25743805
[TBL] [Abstract][Full Text] [Related]
2. High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Wang L; Gu F; Liu CY; Wang RJ; Li J; Xu JY
Tumour Biol; 2013 Apr; 34(2):853-8. PubMed ID: 23242609
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
[TBL] [Abstract][Full Text] [Related]
4. Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.
Xue YZ; Sheng YY; Liu ZL; Wei ZQ; Cao HY; Wu YM; Lu YF; Yu LH; Li JP; Li ZS
Tumour Biol; 2013 Apr; 34(2):895-9. PubMed ID: 23247867
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
6. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
[TBL] [Abstract][Full Text] [Related]
7. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
8. Annexin A2 and CD105 expression in pancreatic ductal adenocarcinoma is associated with tumor recurrence and prognosis.
Huang YK; Liu H; Wang XZ; Zhu S
Asian Pac J Cancer Prev; 2014; 15(22):9921-6. PubMed ID: 25520129
[TBL] [Abstract][Full Text] [Related]
9. Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis.
Zhao ZK; Wu WG; Chen L; Dong P; Gu J; Mu JS; Yang JH; Liu YB
Tumour Biol; 2013 Jun; 34(3):1473-7. PubMed ID: 23355337
[TBL] [Abstract][Full Text] [Related]
10. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Koga A; Sato N; Kohi S; Yabuki K; Cheng XB; Hisaoka M; Hirata K
Pancreatology; 2017; 17(1):115-122. PubMed ID: 28012880
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific membrane antigen as a marker of pancreatic cancer cells.
Ren H; Zhang H; Wang X; Liu J; Yuan Z; Hao J
Med Oncol; 2014 Mar; 31(3):857. PubMed ID: 24477651
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinical significance of HSPA2 in pancreatic ductal adenocarcinoma.
Zhang H; Gao H; Liu C; Kong Y; Wang C; Zhang H
Diagn Pathol; 2015 Mar; 10():13. PubMed ID: 25890028
[TBL] [Abstract][Full Text] [Related]
13. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of mixed lineage kinase domain-like protein expression in the survival of patients with gastric caner.
Ertao Z; Jianhui C; Kang W; Zhijun Y; Hui W; Chuangqi C; Changjiang Q; Sile C; Yulong H; Shirong C
Tumour Biol; 2016 Oct; 37(10):13679-13685. PubMed ID: 27473085
[TBL] [Abstract][Full Text] [Related]
15. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer.
Chikamoto A; Inoue R; Komohara Y; Sakamaki K; Hashimoto D; Shiraishi S; Takamori H; Yamashita YI; Yoshida N; Yamanaka T; Yamashita Y; Baba H
Ann Surg Oncol; 2017 Jul; 24(7):2040-2046. PubMed ID: 28180987
[TBL] [Abstract][Full Text] [Related]
16. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma.
Zhang J; Jiang X; Zhang J
World J Surg Oncol; 2014 Mar; 12():49. PubMed ID: 24581082
[TBL] [Abstract][Full Text] [Related]
18. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
19. Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors.
Keleg S; Titov A; Heller A; Giese T; Tjaden C; Ahmad SS; Gaida MM; Bauer AS; Werner J; Giese NA
PLoS One; 2014; 9(6):e100178. PubMed ID: 24932730
[TBL] [Abstract][Full Text] [Related]
20. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]